Loading…
← CockpitCompetitor Analysis › 603301.SS Zhende Medical Co., Ltd. Class AOpen in the cockpit ↗

Zhende Medical Co., Ltd. Class A603301.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese maker of medical dressings, cotton products and disposable protective and hygiene consumables.

≈ A Chinese Cardinal Health-lite for wound-care/disposable consumablesMomentum leader 87
Mkt cap
$3.26B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$9.88M
20-day average traded
Fwd P/E
42.5×
forward earnings
ROIC−WACC
-0.5 pp
WACC 7.1%
Hurdle
+39 pp
Req g minus delivered
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥82.90
1D+1.1%
1W-3.6%
1M+3.6%
3M-1.5%
6M-9.8%
YTD+17.6%
1Y-12.4%
ATR %3.2%
52w lowhigh20.9% off high

What Zhende Medical does

Chinese maker of medical dressings, cotton products and disposable protective and hygiene consumables.

In one line: A Chinese Cardinal Health-lite for wound-care/disposable consumables.

Products and services

  • Medical dressings/bandages
  • Cotton/gauze products
  • Disposable protective supplies

Customers

  • Hospitals
  • Pharmacies/distributors

Where it sits in the supply chain

  • Health Care
  • Medical supplies
  • Wound care & disposable medical…

What could go right

  • Hospital/PPE consumables demand

What could go wrong

  • Commodity pricing competition
  • Raw material cost swings

Moat: none. Commodity medical-consumables manufacturing with limited pricing power.

Headquarters: Shaoxing, Zhejiang, China · Employees: 7,909

Named competitors

Zhende Medical at a glance

Size Zhende Medical (603301.SS) is a China Health Care company (Medical Specialties) with a market value of $3.26B, the 743rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥82.90 on 18 Nov 2026.

Performance Over six months the shares fell 9.8%, against +11.1% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 7.7% over the last twelve months (peer median +7.2%); the operating margin is 7.3% (peer median 7.4%).

Valuation It trades at 42.5× forward earnings against a peer median of 25.7× (6th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is -16%, so the hurdle is +39 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.5 points below its cost of capital (7.1% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 112603301.SS 88
Six months, rebased to 100: Zhende Medical against the median of its 20 peers (local-currency closes).

Zhende Medical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥4.65BCN¥4.31BCN¥4.25BCN¥4.11BCN¥6.11B
Revenue growth—+1%+3%-33%—
Gross profitCN¥1.74BCN¥1.32BCN¥1.33BCN¥1.32BCN¥2.03B
EBITDAn/aCN¥604MCN¥603MCN¥460MCN¥1.01B
Net incomeCN¥295MCN¥261MCN¥385MCN¥198MCN¥680M
Free cash flowCN¥139M-CN¥5.42M-CN¥309M-CN¥147MCN¥492M
Capital expenditureCN¥347MCN¥550MCN¥770MCN¥599MCN¥754M
Total debtCN¥1.43BCN¥1.34BCN¥625MCN¥666MCN¥647M

Quarterly statements and history in the cockpit →

Zhende Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%688301300003IRTCTMDXAFX603658PLSEAXGN688114AMBU-B4203TECN6030141SXPATRCNVSTCOTN002432CELCCDNA603301.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Zhende Medical is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×100×200×688301300003IRTCTMDXAFXAXGN4203TECNATRCNVSTCOTN002432CDNA603301.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhende Medical is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%300003IRTCTMDXAFX603658AXGN688114TECN6030141SXP002432603301.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhende Medical is the large dot.

Zhende Medical competitors and peer comparison

Head to head with its named competitors (603301.SS vs 300888.SZ vs 300677.SZ vs 1066.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Zhende Medical 603301.SS$3.26B-10%+8%7%42.5×22.9%
Winner Medical 300888.SZ$2.53B-6%+4%11%19.9×-5.2%
Intco Medical Technology 300677.SZ$4.82B-2%+33%20%18.5×-3.5%
Shandong Weigao Group Medical Polymer 1066.HK$1.82B-8%+7%14%8.2×-12.6%
ConvaTec CTEC.L$6.78B+37%+2%16%17.7×17.2%
Smith & Nephew SN..L$12.6B+1%+2%17%14.2×11.1%

How Zhende Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhende Medical against its 20 peers (data as of 18 Nov 2026)
Measure603301.SSPeer medianRank in peer set
1-month return+3.6%-3.4%8th highest of 21
6-month return-9.8%+11.1%7th lowest of 21
Distance from 52-week high-20.9%-27.7%8th highest of 21
Revenue growth (TTM)+7.7%+7.2%10th highest of 20
Operating margin7.3%7.4%10th highest of 19
Forward P/E42.5×25.7×6th most expensive of 18
Growth the price implies (Req g, 7 yrs)22.9%12.5%7th most demanding of 16
Growth delivered (Del g)-16.1%+8.9%lowest of 16
Hurdle (Req g minus delivered)+39.0 pp+1.6 pp3rd most demanding of 16
ROIC minus cost of capital-0.5 pp-2.1 pp5th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhende Medical 603301.SSChina$3.26B-10%+8%7%42.5×22.9%-16.1%
iRay Technology 688301.SSChina$3.31B-30%+58%24%25.7×n/an/a
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%24.4×8.7%-4.2%
iRhythm IRTCUnited States$3.19B-19%+22%5%99.8×46.9%+23.0%
TransMedics TMDXUnited States$3.35B+42%+28%12%43.4×38.4%+88.2%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%24.4×12.5%+10.8%
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%20.3×-0.4%+7.2%
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%n/an/an/a
Axogen AXGNUnited States$3.40B+33%+24%-5%87.3×52.6%+14.9%
MGI Tech 688114.SSChina$3.06B-4%+2%-7%n/a43.7%-0.1%
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%28.8×10.0%+10.0%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
AtriCure ATRCUnited States$2.82B+91%+14%3%212.4×54.2%+20.9%
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
COMET COTN.SWSwitzerland$2.78B-15%-3%6%32.8×n/an/a
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%
Celcuity CELCUnited States$2.73B-60%n/an/an/an/an/a
CareDx CDNAUnited States$3.91B+252%+39%1%50.6×n/an/a

Questions

Who are Zhende Medical's main competitors?
Named competitors: Winner Medical (300888.SZ), Intco Medical (300677.SZ), Shandong Weigao Group Medical Polymer (1066.HK), Convatec Group (CTEC.L), Smith & Nephew (SN..L). The cockpit's measured peer set (industry) also includes iRay Technology (688301.SS), Lepu Medical Technology (Beijing) (300003.SZ), iRhythm (IRTC), TransMedics (TMDX), Carl Zeiss Meditec (AFX.DE), Autobio Diagnostics (603658.SS).
Is Zhende Medical expensive compared with its peers?
On forward p/e it trades at 42.5× against a peer median of 25.7×, 6th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is -16%, so the hurdle is +39 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Zhende Medical stock performed?
Over six months to 18 Nov 2026 the shares returned -9.8% against +11.1% for the median peer; over one year -12.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.